Secondary acute myelogenous leukemia in patients with retinoblastoma: is

GOMBOS DS, HUNGERFORD J, ABRAMSON DH, KINGSTON J, CHANTADA G, DUNKEL IJ, ANTONELI

OPHTHALMOLOGY

Año: 2007 p. 1378 - 1383

0161-6420

PURPOSE: To describe a series of patients with secondary acute myelogenousleukemia (sAML) and retinoblastoma (RB). DESIGN: Retrospective observationalcases series. PARTICIPANTS: Ocular and pediatric oncologists at referral centers in Europe and the Americas and the RB databases at the National Institutes ofHealth and the Ophthalmic Oncology Service at Memorial Sloan-Kettering CancerCenter. METHODS: Physician survey, retrospective database review, and literature search. MAIN OUTCOME MEASURES: History of RB and development of sAML, management of RB (surgery, radiotherapy, chemotherapy), age at diagnosis of RB and leukemia,French-American-British (FAB) subtype, and current status of patient (alive ordead). RESULTS: Fifteen patients with sAML were identified; 13 occurred inchildhood. Mean latent period from RB to AML diagnosis was 9.8 years (median, 42 months). Nine cases were of the M2 or M5 FAB subtypes. Twelve patients (79 %) hadreceived chemotherapy with a topoisomerase II inhibitor, 8 (43%) had receivedchemotherapy with an epipodophyllotoxin. Ten children died of their leukemia.CONCLUSIONS: Acute myelogenous leukemia is a rare secondary malignancy amongretinoblastoma patients, many of whom were treated with primary or adjuvantchemotherapy. Additional studies are needed to assess potential risk factorscontributing to sAML development in this cohort.